Erratum
for
McDermott et al., J Clin Oncol 23 (1) 133-141.
Journal of Clinical Oncology, Vol 23, No 12 (April 20), 2005: pp. 2877
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.03.907
ERRATUM
The January 1, 2005, article by McDermott et al entitled, "Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma" (J Clin Oncol 23:133-141, 2005) contained two errors.
The results section of the abstract mistakenly states that the median response durations were 14 and 7 months (P = .14) for high-dose IL-2 and outpatient IL-2 and IFN, respectively. The correct median response durations are 24 and 15 months (P = .18).
The Authors Disclosures of Potential Conflicts of Interest section contained an omission. David F. McDermott received more than $2,000 per year from Chiron for either of the last 2 years.
The online version of the article was corrected in departure from the print.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
|